ENDPOINTS

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer

Plus, news about Tribune Therapeutics and Leap Therapeutics: Humacyte’s $50M offering: The North Carolina biotech is selling 25 million shares at $2.00 apiece, which is nearly 30% lower than its closing ...

Mar 26, 2025 - 15:11
 0
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer
Plus, news about Tribune Therapeutics and Leap Therapeutics: Humacyte’s $50M offering: The North Carolina biotech is selling 25 million shares at $2.00 apiece, which is nearly 30% lower than its closing ...
Read More

Tags:

Previous Article

Regulating the DTC Telehealth Boom: How Policies Are Shaping the Future of Presc...

Next Article

Infinite Reality Acquires Napster for $200M to Create Social Music Platform & Vi...

Related Posts

New Flagship startup aims to trailblaze ‘AI science factories’

New Flagship startup aims to trailblaze ‘AI science fac...

Mar 10, 2025  0

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor...

Feb 14, 2025  0

Sixteen-year-old dies after receiving Sarepta’s Duchenne therapy Elevidys

Sixteen-year-old dies after receiving Sarepta’s Duchenn...

Mar 18, 2025  0